Nurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader Program
Nurix Therapeutics (NRIX) shares fell 40% after Sanofi terminated a Phase 1 clinical trial for SAR448272, a STAT6 degrader. Nurix won't receive future milestone payments or royalties for this program but retains other licensed programs. The company's cash runway remains unchanged, with $1.1B expected to last into 2H 2029. Nurix's other programs, including bexobrutideg and NX-1607, are progressing in clinical trials.
How this was made
The 30-second read
Why it matters
The discontinuation removes a potential revenue stream, intensifying downside risk for NRIX shares.
Market read
The news triggered a 40% share decline, indicating high immediate market relevance for traders.
What to watch
Nurix retains eligibility for other Sanofi milestones and has strong cash reserves through 2029.
Background
Nurix Therapeutics focuses on targeted protein degradation; its collaboration with Sanofi includes multiple programs.
Ticker impact
Sanofi discontinued the Phase 1 trial of Nurix's STAT6 degrader, causing a 40% share drop.
likely continued pressure as investors reassess the partnership value
The news is a primary disclosure of a major program termination with a large same‑day price move.
Market effects
Biotech firms with similar partnership models may see heightened scrutiny on trial risk.
US biotech sector faces modest negative sentiment.
Limited to investors tracking protein‑degradation platforms.
Counterpoint
The remaining pipeline assets and cash runway could support a rebound if other programs advance.
Key entities
- companyNurix Therapeutics, Inc.
Clinical‑stage biopharma developing protein degraders.
- companySanofi
Pharmaceutical partner terminating the STAT6 program.
